ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Hypertension
The Burden of Hypertensive Heart Disease in China and G20 Countries: Analysis from 1990 to 2021 and 30-Year Projections for China
Guangzhou University of Traditional Chinese Medicine Shenzhen Hospital, Shenzhen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Background: Hypertensive heart disease (HHD) poses a major global public health challenge. This study provides updated estimates of the HHD burden in China and G20 countries from 1990 to 2021 and projects China's trends to 2051. Methods: Using data from the Global Burden of Disease 2021 study, we analyzed HHD prevalence, mortality, DALYs, and age-standardized rates (ASPR, ASDR) for China and G20 countries. Joinpoint regression was used to calculate annual percentage change (APC) and average annual percentage change (AAPC). An ARIMA model projected China's incidence for 2021-2051. Results: In 2021, China reported 39.12 million HHD cases, 32.81 million deaths, and 55.89 million DALYs, with ASPR, ASDR, and DALY rates of 192.47, 18.85, and 292.54 per 100,000, respectively. G20 countries had 90.81 million cases, 89.67 million deaths, and 160.18 million DALYs, with corresponding rates of 139.64, 14.06, and 248.75 per 100,000. From 1990 to 2021, AAPCs for ASPR and ASDR showed no significant changes in China or G20 countries. China's rates consistently exceeded G20 averages, with no marked gender differences. Projections indicate a rising ASPR but slightly declining ASDR in China by 2051. Conclusion: Both China and the G20 group exhibit a pronounced upward trend in HHD prevalence and mortality, likely attributable to the backdrop of population aging. Conversely, China's declining prevalence and mortality rates may benefit from advances in medical technology.Furthermore, China's ASPR is projected to increase annually over the next 30 years. These findings underscore the imperative to strengthen prevention, control, and treatment strategies, providing crucial evidence for healthcare planning and practice.
Summary
Keywords
Disability-adjusted life years, Hypertensive heart disease, Joinpoint regression, Mortality, Prevalence
Received
20 October 2025
Accepted
13 January 2026
Copyright
© 2026 Zhang, Peng, Chen and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xinzheng Tang
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.